Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
NASDAQ:OCUL
Price:
6.24 USD
-0.79%
Updated:
May 21, 2024
Ocular Therapeutix Inc
Cash from Financing Activities
|
Ocular Therapeutix Inc
Cash from Financing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Cash from Financing Activities
$491m
|
CAGR 3-Years
32%
|
CAGR 5-Years
45%
|
CAGR 10-Years
54%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$21.4B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$8.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$23.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$5.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$2.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Ocular Therapeutix Inc's Cash from Financing Activities?
Cash from Financing Activities
491m
USD
491m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Cash from Financing Activities amounts to 491m USD.
What is Ocular Therapeutix Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
54%
54%
Over the last year, the Cash from Financing Activities growth was 34 969%. The average annual Cash from Financing Activities growth rates for Ocular Therapeutix Inc have been 32% over the past three years , 45% over the past five years , and 54% over the past ten years .
You don't have any saved screeners yet
